Compounds > gefitinib
Page last updated: 2024-09-03

gefitinib and trametinib

gefitinib has been researched along with trametinib in 10 studies

Compound Research Comparison

Studies
(gefitinib)		Trials
(gefitinib)		Recent Studies (post-2010)
(gefitinib)		Studies
(trametinib)		Trials
(trametinib)		Recent Studies (post-2010) (trametinib)
5,2315662,919940134926

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)trametinib (IC50)
Dual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)0.0043
Dual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)0.0011

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (60.00)24.3611
2020's4 (40.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Bharate, SB; Raghuvanshi, R1
Caballero, E; García-Cárceles, J; Gil, C; Martínez, A1
Beck, S; Frejno, M; Klaeger, S; Koch, H; Kuster, B; Ruprecht, B; Wilhelm, M1
Bi, F; Dai, X; Fan, Z; Gong, Q; Tang, Q; Wei, G; Xia, H; Yu, H; Zhou, S1
Ali, R; Brown, W; Davisson, VJ; Purdy, SC; Wendt, MK1
Chen, C; Liang, Z; Liu, D; Poteet, E; Van Buren, G; Yao, Q1
Acar, A; Banerji, U; Barozzi, I; Burke, R; Caravagna, G; Cresswell, GD; Fernandez-Mateos, J; Hong, SP; Magnani, L; Maley, CC; Nichol, D; Sottoriva, A; Spiteri, I; Stewart, A; Stubbs, M; Trahearn, N; Valeri, N; Vlachogiannis, G; Werner, B1
Li, W; Li, Y; Liu, Y; Tian, P; Wang, K; Zeng, H1

Reviews

1 review(s) available for gefitinib and trametinib

ArticleYear
Kinase Inhibitors as Underexplored Antiviral Agents.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses

2022

Other Studies

9 other study(ies) available for gefitinib and trametinib

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases

2022
Phosphoproteome Profiling Reveals Molecular Mechanisms of Growth-Factor-Mediated Kinase Inhibitor Resistance in EGFR-Overexpressing Cancer Cells.
    Journal of proteome research, 2016, 12-02, Volume: 15, Issue:12

    Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Humans; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Phosphopeptides; Protein Kinase Inhibitors; Proteome; Proteomics; Pyridones; Pyrimidinones; Quinazolines

2016
EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy.
    Cell death & disease, 2018, 02-15, Volume: 9, Issue:3

    Topics: 3-Phosphoinositide-Dependent Protein Kinases; Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinase; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Signal Transduction; Simvastatin; Sorafenib; Transcription Factors; YAP-Signaling Proteins

2018
Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand.
    Cell death & disease, 2018, 09-24, Volume: 9, Issue:10

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Ligands; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Signal Transduction; STAT1 Transcription Factor

2018
Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib.
    PloS one, 2019, Volume: 14, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; GPI-Linked Proteins; Humans; Mesothelin; Pancreatic Neoplasms; Pyridones; Pyrimidinones; Signal Transduction; Transforming Growth Factor alpha; Tumor Cells, Cultured

2019
Exploiting evolutionary steering to induce collateral drug sensitivity in cancer.
    Nature communications, 2020, 04-21, Volume: 11, Issue:1

    Topics: Antineoplastic Agents; Clonal Evolution; Computational Biology; Computer Simulation; Drug Resistance, Neoplasm; Evolution, Molecular; Gefitinib; Genotype; Humans; Lung Neoplasms; Models, Theoretical; Molecular Medicine; Pyridones; Pyrimidinones; Stochastic Processes

2020
Acquired BRAF N581S mutation mediated resistance to gefitinib and responded to dabrafenib plus trametinib.
    Lung cancer (Amsterdam, Netherlands), 2020, Volume: 146

    Topics: Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Imidazoles; Lung Neoplasms; Mutation; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones

2020